HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a $41 price target.

February 28, 2024 | 6:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Syndax Pharmaceuticals with a $41 price target.
The reiteration of a Buy rating and maintenance of a $41 price target by a reputable analyst like Edward White could instill confidence among investors and potentially lead to a positive short-term impact on SNDX's stock price. Analyst ratings, especially from well-regarded firms, often influence investor sentiment and can lead to price movements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100